Nucleophosmin (NPM1) is a nucleolar protein that is frequently overexpressed in various types of solid tumors. NPM1 is involved in several cellular processes that might contribute significantly to the increased proliferation potential of cancers. Previous reports suggest that NPM1 expression is highly increased in response to mitogenic and oncogenic signals, the mechanisms of which have not been elucidated extensively. Using constructs incorporating different fragments of the NPM1 promoter upstream to a Luciferase reporter gene, we have identified the minimal promoter of NPM1 and candidate transcription factors regulating NPM1 promoter activity by luciferase reporter assays. We have validated the roles of a few candidate factors at the transcriptional and protein level by quantitative reverse transcriptase PCR, immunoblotting and immunohistochemistry, and explored the mechanism of regulation of NPM1 expression using immunoprecipitation and chromatin immunoprecipitation assays. We show here that the expression of NPM1 is regulated by transcription factor c-fos, a protein that is strongly activated by growth factor signals. In addition, mutant p53 (R175H) overexpression also enhances NPM1 expression possibly through c-myc and c-fos. Moreover, both c-fos and mutant p53 are overexpressed in oral tumor tissues that showed NPM1 overexpression. Collectively, our results suggest that c-fos and mutant p53 R175H positively regulate NPM1 expression, possibly in synergism, that might lead to oncogenic manifestation.
Nucleophosmin (NPM1) is a nucleolar protein that is frequently overexpressed in various types of solid tumors. NPM1 is involved in several cellular processes that might contribute significantly to the increased proliferation potential of cancers. Previous reports suggest that NPM1 expression is highly increased in response to mitogenic and oncogenic signals, the mechanisms of which have not been elucidated extensively. Using constructs incorporating different fragments of the NPM1 promoter upstream to a Luciferase reporter gene, we have identified the minimal promoter of NPM1 and candidate transcription factors regulating NPM1 promoter activity by luciferase reporter assays. We have validated the roles of a few candidate factors at the transcriptional and protein level by quantitative reverse transcriptase PCR, immunoblotting and immunohistochemistry, and explored the mechanism of regulation of NPM1 expression using immunoprecipitation and chromatin immunoprecipitation assays. We show here that the expression of NPM1 is regulated by transcription factor c-fos, a protein that is strongly activated by growth factor signals. In addition, mutant p53 (R175H) overexpression also enhances NPM1 expression possibly through c-myc and c-fos. Moreover, both c-fos and mutant p53 are overexpressed in oral tumor tissues that showed NPM1 overexpression. Collectively, our results suggest that c-fos and mutant p53 R175H positively regulate NPM1 expression, possibly in synergism, that might lead to oncogenic manifestation.
Introduction
Nucleophosmin (NPM1) is a multifunctional protein that is predominantly nucleolar and described to have oncogenic as well as tumor suppressor properties. Deletion or mutation of NPM1 is commonly found in hematological malignancies such as acute myeloid leukemia, acute promyelocytic leukemia, anaplastic large cell lymphoma, and in premalignant myelodysplastic syndrome [1] . On the contrary, NPM1 is overexpressed in human tumors of diverse histological origins such as gastric [2] , colon [3] , breast [4] , ovary [5] , bladder [6] , oral [7] , thyroid [8] , brain [9] , liver [10] , prostate [11, 12] and multiple myeloma [13] . NPM1 overexpression correlates well with the clinical features of cancer in some of the cases. For example, overexpression of NPM1 in hepatocellular carcinoma correlates well with clinical prognostic parameters such as serum alpha fetal protein levels, tumor pathological grading and liver cirrhosis [10] , suggesting that NPM1 overexpression could serve as a diagnostic marker for hepatocellular carcinoma. NPM1 overexpression and hyperacetylation progress according to the increasing grade of the tumor in oral squamous cell carcinoma (OSCC) [7] . Moreover, NPM1 overexpression also correlates well with recurrence and progression of bladder cancer to advanced stages [6] and is associated with acquired estrogen-independence in human breast cancer cells [4] . In gastric cancer, NPM1 expression is correlated with resistance to the drug oxaliplatin [14] .
Notably, NPM1 is a direct transcriptional target of oncogenic transcription factor c-myc [15] and NPM1 overexpression alone can promote the transformation of NIH3T3 mouse fibroblast cells [16] . NPM1 suppresses apoptosis and promotes DNA repair thereby aiding in the survival of tumor cells where NPM1 is overexpressed [1, 17] . In addition, NPM1 overexpression promotes cell division and growth, presumably through stimulatory effects on ribosomal DNA (rDNA) transcription, ribosome subunit export and DNA replication during S phase [1] . NPM1 overexpression also interferes with ARF (Alternate reading frame product of the CDKN2A locus)-mediated activation of p53 thereby further contributing to oncogenesis. Similar to oncogenes such as Ras, overexpression of NPM1 also causes cellular senescence in human fibroblast cells [18] . Moreover, NPM1 is induced upon mitogenic signals in T cells, B cells and the mouse fibroblast Swiss 3T3 cells [19] [20] [21] . All these studies suggest that NPM1 overexpression promotes tumor development and hence could function as a proto-oncogene. NPM1 is also known to respond to various cellular stresses. NPM1 mRNA, as well as protein levels, are rapidly induced in response to ultraviolet radiation or thymine dinucleotide treatment that mimics a DNA damage signal [22] . It is also induced in hypoxic conditions in normal and cancerous cells through HIF-1a (Hypoxia inducible factor 1 alpha subunit) binding to its promoter and prevents apoptosis of cells in these conditions [23] . These studies show that NPM1 expression is regulated by oncogenic signals and cellular stresses and hence it is of vital importance to study the regulation of NPM1 gene expression.
Till date, there are only a few reports that have tried to address the regulation of NPM1 expression at the level of transcription. The first study on NPM1 gene regulation showed that the NPM1 promoter has a Yin Yang 1 (YY1) binding site at À371 to À344 nucleotide position upstream to the transcription start site (TSS) [24] . Subsequently, it was shown that the YY1 response element on NPM1 promoter is bound by YY1-HDAC (histone deacetylase) repressor complex. Upon infection by Hepatitis C virus (HCV), the YY1-HDAC repressor complex is replaced by the YY1-p300-NPM1-HCV core transcription activation complex, relieving its repression and inducing NPM1 expression during HCV infection [25] . NPM1 has also been identified as a myc responsive gene by a subtractive hybridization screen [15] . Ras signaling leads to c-myc recruitment to the NPM1 promoter in U1 bladder cancer cells [26] . Conversely, differentiation of human leukemic HL-60 cells into mature granulocytic cells by retinoic acid (RA) leads to reduction in total c-myc levels as well as on NPM1 promoter and consequently to a reduction in NPM1 levels [27] . Further, Interferon alpha (IFN-a) stimulation of Jurkat cells (immortalized T lymphocyte cells) causes increased phosphorylation of Signal transducer and activator of transcription 3 (STAT3) that enhances its nuclear localization and binding to the NPM1 promoter, leading to a concomitant rise in NPM1 expression levels. Interestingly, NPM1 binds to phospho-STAT3 and is responsible for its nuclear translocation [28] . A recent report suggests that mTOR (mechanistic target of rapamycin) kinase transcriptionally regulates NPM1 expression by directly binding to the NPM1 promoter [29] . Although these studies shed some light into the regulation of NPM1 expression, a systematic study investigating the involvement of other oncogenic transcription factors apart from c-myc has been lacking.
Here, we show that NPM1 gene is regulated by an important oncogenic transcription factor c-fos/AP-1 and a prevalent gain-of-function mutant of tumor suppressor p53, R175H, whereas wild-type (WT) p53 has no appreciable effect on NPM1 expression. Moreover, c-fos and mutant p53 levels are significantly upregulated in tumor tissues where NPM1 overexpression is observed confirming the role of a mutp53-c-fos axis in upregulating NPM1 expression in the context of cancer.
Results

Characterization of human NPM1 promoter
To understand the regulation of NPM1 expression, we set out to systematically characterize the regulatory elements of the human NPM1 gene. NPM1 gene is present on the long arm (5q35.1) of chromosome 5. The sequence co-ordinates for NPM1 gene locus according to NCBI accession no. NC_000005.9 are 170814708 to 170837888 in the hg19 assembly of the human genome. The TSS as reported in NCBI database is located at position 170814708, however, it differs from the experimentally identified TSS [24] .The translation start codon ATG is present 246 bp downstream to the database TSS and is contained within exon 1. We consider the database TSS as +1 or TSS for all future references. In order to identify the minimal promoter for NPM1 gene, several fragments containing sequences upstream and downstream of the TSS were cloned into the pGL3 basic vector (Fig. 1A) . Luciferase reporter assays were performed after transfection of different NPM1 promoter constructs (refer Fig. 1A ) in HEK293 (human embryonic kidney 293) cells. Among all the promoter constructs, NPM1 Luc 2, 3 and 5 showed the highest relative luciferase activity (Fig. 1A) . Interestingly, the data indicated that the upstream sequences (about 1-2 kb upstream relative to TSS) have maximal promoter activity and may contain activating transcription factorbinding sites. On the other hand, relatively lower luciferase activities (~50-100 fold lower) were observed with constructs containing regions downstream of the TSS especially Intron 1 (NPM1 Luc1 and NPM1 Luc4) (Fig. 1A) . Upon analyzing the sequence upstream and downstream of the NPM1 TSS, we identified the core promoter elements, namely BREu (upstream transcription factor II B (TFIIB) recognition element), BREd (downstream TFIIB recognition element), TATA and INR (Initiator motif) [30] , to be present downstream to the TSS (Fig. 1B) . To further validate the importance of the core promoter elements, we constructed deletion constructs of the NPM1 promoter lacking these promoter elements (Fig. 1C) . Luciferase assays performed using these constructs showed that the deletion of the core promoter elements led to a nearly 100-fold decrease in the promoter activity compared to respective full-length constructs (Fig. 1C) . This result shows that indeed the sequence downstream to the TSS (+1 to +264) contains the core promoter elements and is required for NPM1 promoter activity. However, the upstream sequences may be a part of the upstream regulatory region of NPM1 and contain binding sites for several transcription factors that help in increased transcription of NPM1 gene. We used the upstream 1 kb sequence to predict the transcription factor-binding sites, using TRANSFAC and Consite databases [31] . The predicted transcription factor-binding sites are shown in Tables 1 and 2 , respectively. Interestingly, we found binding sites for numerous transcription factors such as SNAI1, c-fos among others and previously reported factors such as c-myc. Of particular interest to us was c-fos which has been previously implicated in regulating genes involved in cell proliferation. The c-fos protein heterodimerizes with members of the JUN family of proteins such as c-jun, to form the transcriptional activator AP-1 (Activator Protein-1) [32] [33] [34] . The transcription factors, c-fos and c-jun, are categorized as immediate early genes and are the first responders to extracellular signals including growth factors, mitogens, and stress. They provide immediate but short acting signals, leading to varied cellular responses, some of which include differentiation, metabolism, and proliferation [35] .
c-fos is highly expressed in many cancers including breast cancer [36] , endometrial cancer [37] , pancreatic cancer [38] , and hepatocellular carcinoma [39] . The oncogenic mechanism of AP-1 includes regulation of genes involved in invasion, metastasis, angiogenesis, hypoxia to name a few. [40, 41] . The fact that NPM1 expression is induced upon addition of serum, a source of growth factors, [20] suggests NPM1 could be induced downstream of AP-1. Moreover, c-fos and c-jun were also shown to be overexpressed in oral cancers [42, 43] . Interestingly, c-fos expression is considered as a prognostic marker for cancer progression in some cancers, which correlates with our previous study demonstrating NPM1 overexpression and hyperacetylation in increasing grades of oral cancer [7] . These data encouraged us to investigate the role of AP-1 in the overexpression of NPM1 in cancer.
Transcription factor c-fos regulates NPM1 expression
To test whether transcription factor c-fos is involved in regulating NPM1 expression, the coding sequence of cfos gene was cloned into the pFLAG-CMV2 vector. The ability of c-fos to activate NPM1 promoter activity was tested in HEK293 cells by co-transfecting it with NPM1 promoter construct NPM1 Luc 5 (À2069 to +264). A dose-dependent increase in NPM1 promoter activity was observed upon c-fos transfection, and 400 ng of c-fos resulted in approximately 8-fold increase in its activity ( Fig. 2A) . To confirm that c-fos enhances NPM1 promoter activity by binding to the upstream regulatory elements, the luciferase assays were performed with the core promoter deleted construct NPM1 Luc 5 DCP (À2069 to +1) (Fig. 2B) . Significantly, the core-promoter deleted construct showed a similar dose-dependent increase in promoter activity after c-fos transfection (Fig. 2B) .
Deletion of the core-promoter elements did not affect the c-fos induced increase in promoter activity as evident from the similar fold change in luciferase activity ( Fig. 2A versus Fig. 2B ). Furthermore, to confirm that the promoter activation by c-fos is truly relevant to the cellular context, we performed luciferase assays in parallel with YY1, a transcription factor previously reported to activate NPM1 expression. [24] (Fig. 2C) . These results show that c-fos enhances NPM1 promoter activity possibly by binding to the upstream regulatory elements of NPM1 promoter. Transcription factor AP-1 regulates NPM1 expression by directly binding to its promoter
In addition to HEK293 cells, we validated the luciferase reporter assay results in the human non-small cell lung carcinoma cell line, H1299 (Fig. 2D) . c-fos enhanced the NPM1 promoter NPM1 Luc 2 (À1059/ +264) activity in a dose-dependent manner as observed in HEK293 cells. Since c-fos binds to AP-1-binding sites on DNA as a heterodimer with c-jun [32] , we checked the promoter activity of NPM1 upon cotransfection of c-fos and c-jun. Results showed that co-transfection of c-fos and c-jun led to a significant increase in the promoter activity of NPM1 as compared to c-fos or c-jun alone. (Fig. 2E ). This shows that AP-1 (c-fos/c-jun heterodimer) enhances NPM1 promoter activity. We next checked whether c-fos directly binds to NPM1 promoter. We used Consite database to predict the c-fos-binding sites on NPM1
promoter. At 80% cut-off, four putative-binding sites of c-fos were predicted based on the consensus-binding motif. We refer to them as AP-1-binding sites (AP1BS) based on score ( Fig. 2F and Table 3 ). To demonstrate that c-fos binds to the AP-1-binding sites on NPM1 promoter, the four c-fos binding sites were mutated 
Relative fold change pGL3 c-fos Values are mean + SEM from two experiments with two technical replicates per experiment. Statistical significance was calculated using Student's t-test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. using site-directed mutagenesis method as shown in Fig. 2G . Mutation of four AP-1-binding sites on NPM1 promoter led to a decrease in transactivation of the NPM1 promoter by c-fos (Fig. 2H) . However, it did not lead to a complete abolishment of the c-fos mediated activation of NPM1 promoter, which indicated that low-affinity-binding sites of c-fos might contribute to its binding and subsequent transactivation. Next, we also created several point mutations in the DNA-binding domain of c-fos targeting mainly the basic residues, namely K153Q, R155Q, R157Q, R158Q, and R159Q that are important for its DNAbinding activity. Additionally, we mutated critical residues in its leucine zipper region, L179V, L186A, and L193V that are essential for its dimerization with c-jun [44] . The mutant c-fos was unable to activate NPM1 promoter activity as compared to the WT c-fos (Fig. 2I) , which confirms that c-fos directly binds to the NPM1 promoter to enhance its expression. Furthermore, c-fos transfection in H1299 cells led to a significant increase in NPM1 mRNA (Fig. 3A) as well as protein levels (Fig. 3B) . A similar increase in NPM1 mRNA (Fig. 3C ) and protein levels (Fig. 3D ) was observed upon co-transfection of c-fos and c-jun (AP-1) as well. Appreciable increase in NPM1 protein levels were achieved after transfection of higher doses of c-fos or AP-1 (1.5 lg) as compared to that required to observe upregulation at mRNA levels (500 ng of cfos or AP-1). The discordance in the degree of upregulation induced by c-fos or AP-1 transfection could be due to the different doses of transfection. However, we do not exclude the possibility of stabilization of NPM1 protein levels by c-fos. To show that c-fos enhances NPM1 transcription by directly binding to the endogenous NPM1 promoter, we performed chromatin immunoprecipitation (ChIP) assays in cells transfected with c-fos. We found that c-fos occupancy was significantly increased at three tested in silico identified c-fos-binding sites (Fig. 3E-H) . In addition, c-fos occupancy also increased at three other upstream regions that were previously shown to be occupied by c-fos in human cancer cell lines by ENCODE consortium (Fig. 3I-K) [45] . c-fos occupancy was not observed at a negative control region and did not change significantly after c-fos transfection (Fig. 3L) . These results show that c-fos/AP-1 indeed activate NPM1 expression in cells.
c-fos and NPM1 expression correlate well in OSCC cells
We next investigated whether NPM1 is overexpressed in oral tumors showing c-fos overexpression. Immunohistochemistry (IHC) analysis of oral tumor tissue array prepared from samples collected from local clinics, re-confirmed the previous results that NPM1 and c-fos are overexpressed in human oral tumor samples when compared to adjacent normal tissues (Fig. 4A-C) . Moreover, c-fos expression in individual tumor samples correlated significantly (r 2 = 0.49) with NPM1 expression (Fig. 4D) . To further evaluate whether cfos is involved in NPM1 overexpression in OSCC, we tested the effects of c-fos knockdown on NPM1 expression in an oral cancer cell line UPCI:SCC-29B. We used siRNA against c-fos as well as a scrambled siRNA control and measured NPM1 mRNA and protein levels. We achieved~75% knockdown efficiency with c-fos siRNA (Fig. 4E ) as compared to scrambled siRNA control. NPM1 mRNA and protein levels decreased significantly after c-fos knockdown (Fig. 4F,  G) . We also tested c-fos and c-jun (AP-1) knockdown and observed that NPM1 mRNA and protein levels significantly decreased after knockdown of c-fos and c-jun (Fig. 4H-K) . These results indicate that the transcription factor AP-1 is involved in NPM1 overexpression in oral carcinoma.
Since, p53 mutation or loss has been reported to be the cause of 50% of human cancers, we also tested the expression of p53 in the oral tumor tissue arrays with NPM1 and c-fos overexpression. Mutant p53 lose their regulation by Mouse Double Minute 2 (MDM2) and are often overexpressed in tumor cells whereas WT p53 levels are low in normal and tumor cells [46] . Some of these mutants have novel functions distinct from the WT protein that help tumor growth, hence, known as gain-of-function mutants [47] . Interestingly, we found distinct staining pattern of p53 only in a few cells in the section implying the presence of a mutant form of p53 [48] (Fig. 4A) . When we compared the expression levels of p53 with that of NPM1 in the oral tumor samples, we found that tumor samples showing positive staining for p53 expression (p53 High) had higher NPM1 levels ( Fig. 4L and M) as compared to those with negative or lesser staining for p53 expression (p53 Low), indicating a positive correlation between NPM1 and p53 expression in tumor tissues from patient samples. p53 and NPM1 proteins have been shown to interact with each other, leading to an array of consequences. Most notably, NPM1 enhances transcriptional activation by p53 [49] as well as stabilizes p53 by interacting with MDM2 [50] . However, another group has shown that NPM1 is an early responder to DNA damage that prevents premature activation of p53 [51] . Although numerous studies have implicated NPM1 in the p53 pathway [52] [53] [54] , no report exists regarding the transcriptional regulation of NPM1 gene either by wild-type p53 or mutant p53 proteins. These facts along with our finding of the positive correlation between NPM1 and p53 expression in oral tumor tissue samples encouraged us to investigate the role of p53 and its mutants in transcriptional regulation of NPM1 expression. Therefore, we first checked whether WT p53 had any influence on NPM1 gene expression. Values are mean + SEM from three independent experiments. Statistical significance was calculated using one-way ANOVA, Tukey's multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. EV: empty vector.
WT p53 does not alter NPM1 transcript levels
Since we were interested in studying the transcriptional regulation of NPM1 by p53, we checked for presence of p53-binding sites on NPM1 promoter, using Consite database. We found several low-scoring putative p53-binding sites in the 7 kb sequence (À6 kb/+1 kb) of the NPM1 promoter region (eleven sites at 60% cut off; data not shown). Transcriptional effect of p53 on endogenous NPM1 expression was investigated by expressing WT p53 in H1299 p53 null cells. WT p53 expression did not significantly alter the NPM1 transcript levels (Fig. 5A ) although p53 protein was highly expressed after transfection (Fig. 5B) . In an alternate approach, human colorectal carcinoma cells, HCT116 p53
, expressing WT p53 were treated with increasing doses of Nutlin-3a, an MDM2 inhibitor that stabilizes p53 protein and enhances its level in cells. NPM1 transcript levels did not alter significantly upon Nutlin-3a treatment (Fig. 5C ) whereas the known p53 responsive gene p21 or cyclin-dependent kinase inhibitor 1A (CDKN1A) levels increased significantly as expected in a dose-dependent manner under the same conditions (Fig. 5D) showing that indeed p53 protein levels were upregulated. These results show that WT p53 does not transcriptionally alter NPM1 levels. This observation was explained by the absence of highscoring p53-binding sites in the NPM1 promoter sequence as analyzed and mentioned earlier. NPM1 protein levels were also checked by western blot analysis upon treatment with increasing doses of Nutlin-3a for 6 and 12 h. There was no significant alteration observed in the NPM1 protein levels upon treatment with Nutlin-3a (Fig. 5E , compare lanes 3-6 versus lanes 1 and 2 and Fig. 5F ).
Mutant p53 (R175H) enhances NPM1 expression
Our observation of WT p53 not significantly regulating NPM1 expression, does not eliminate the possibility of the role of p53 mutants in this process, given the fact that many hot-spot p53 mutants act in a gainof-function manner regulating specific sets of genes by their unique mechanisms which are different from that of WT p53 [47, 55] . Hence, to test this hypothesis, we checked whether mutant p53 could activate NPM1 expression. p53 has six hotspot residues that are frequently mutated in all types of cancer. Among these, R175H is the most frequent mutation and it is the fourth frequent mutation across all cancer types considering all gene mutations [55] . R175H is a gainof-function conformational mutant of p53 that does not bind to DNA without the help of accessory factors. Hence, we first tested the effect of R175H p53 expression on NPM1 promoter activity. Co-transfection of NPM1 promoter NPM1 Luc 2 (À1059/+264) with R175H p53 expression plasmid led to an increase in the NPM1 promoter activity in a dose-dependent manner (Fig. 6A ). R175H p53 transfection in H1299 cells resulted in a significant increase in NPM1 mRNA (Fig. 6B ) and protein levels (Fig. 6C) . Moreover, R175H overexpression in a p53 null oral cancer cell line UM-SCC-1 induced NPM1 protein levels as well Values are mean + SEM from two independent experiments and three technical replicates from each experiment. Statistical significance was calculated using Student's t test. *P < 0.05, **P < 0.01, ***P < 0.001. (Fig. 6D) . These results show that R175H p53 indeed transcriptionally activates NPM1 expression in cells. However, the mechanism of R175H-mediated transactivation of NPM1 expression is unclear. We also screened a few other hot-spot mutants of p53 such as R249S and R273H p53. None of these mutants could induce NPM1 transcript levels ( Fig. 6E and F) even when similar levels of protein expression were achieved for each mutant after transfection (Fig. 6G) implying that the effects of R175H p53 on NPM1 expression were specific to this mutant. Since these mutants did not enhance NPM1 transcript levels, we did not further check NPM1 protein levels as we were particularly interested in investigating the transcriptional regulation of NPM1 by mutant p53. We subsequently validated the expression of some of the known targets of R175H p53. Expression of important cell cycle genes such as cyclin A2 (CCNA2), cyclin B2 (CCNB2), cell division cycle 25C (CDC25C), and cyclindependent kinase 1 (CDK1) were enhanced by overexpression of R175H p53 as was reported earlier [55] ( Fig. 6H-K) . Interestingly, these genes are targets of the nuclear transcription factor Y (NF-Y) as well. R175H p53 was previously reported to interact with NF-Y and induce the expression of these NF-Y target genes [47] . Additionally, we also observed that c-myc mRNA levels were enhanced upon R175H expression in H1299 cells as reported earlier [56] (Fig. 6L) . Presumably, the increased expression of all these genes along with NPM1 contribute collectively to the process of tumorigenesis.
c-fos interacts with and recruits R175H to NPM1 promoter
Given that c-fos and R175H p53 transcriptionally activate NPM1 expression and R175H itself is unable to bind to the DNA to cause gene transactivation, we tested if c-fos and R175H could interact, leading to recruitment of mutant p53 to the NPM1 promoter. Co-immunoprecipitation results showed that mutant p53 was pulled down with FLAG-c-fos in H1299 cells co-transfected with R175H p53 and FLAG-c-fos (Fig. 7A) , indicating that these two proteins interact. Moreover, c-fos and R175H p53 seem to colocalize in the nucleus as observed by co-immunofluorescence analyses (Fig. 7B ). In addition, we performed coimmunoprecipitation assays with R249S and R273H to evaluate whether the interaction with c-fos was specific to R175H p53. Results showed that R249S and R273H also bind to c-fos which might be artificially induced due to overexpression of both proteins (Fig. 7C) . To evaluate whether c-fos binds to R175H
at endogenous levels, we performed the co-immunoprecipitation experiment in AU565 cell line which contains naturally mutated R175H p53. Results showed that R175H p53 is indeed pulled down with c-fos immunoprecipitation indicating that R175H p53 indeed binds to c-fos (Fig. 7D) . Next, in order to study the effect of R175H overexpression on the endogenous c-fos binding on NPM1 promoter, we made a stable cell line with doxycycline-inducible expression of R175H p53. We confirmed the doxycycline-induced expression of FLAG-tagged R175H p53 using immunofluorescence and western blot assays ( Fig. 7E and F) . Doxycycline-induced expression of R175H enhanced NPM1 expression at both protein ( Fig. 7F ) and RNA levels (Fig. 7G) . c-fos transcript levels were not significantly altered by the induction of R175H expression, indicating that R175H does not have a direct effect on the levels of c-fos itself (Fig. 7H) . However, R175H overexpression enhanced the occupancy of c-fos on NPM1 promoter at the cfos/AP-1-binding sites as observed by ChIP assays (Fig. 8A-F) . Interestingly, R175H itself was recruited at the AP-1-binding sites upon doxycycline-mediated induction ( Fig. 8G and H) . In accordance with previous reports [55] , we also validated the enrichment of R175H p53 at known target promoters of the cell cycle genes CCNA2, CDC25C and CDK1 by ChIP assays (Fig. 8I-K) . To investigate whether the presence of R175H p53 affects the induction of NPM1 expression by c-fos, we tested NPM1 expression levels with c-fos overexpression with or without doxycycline treatment.
Results showed that in the presence of R175H p53, cfos overexpression led to highest amount of NPM1 protein expression (Fig. 8L, compare lanes 2 versus 4) . c-fos and R175H p53 were individually able to induce NPM1 levels although at lower levels than when present together (Fig. 8L) . Altogether, these results show that R175H might induce c-fos recruitment to the NPM1 promoter by an unknown mechanism and cfos, in turn, could recruit R175H p53 to the NPM1 promoter, thereby enhancing NPM1 expression levels.
Discussion
Nucleophosmin is frequently overexpressed in several types of solid tumors. However, the mechanisms driving the increased expression of NPM1 are largely unknown. Here, we show that c-fos and R175H p53 activate NPM1 gene expression at the transcript level that was consistent at the protein levels as well. c-fos forms heterodimer with c-jun through their leucine zipper domains forming the AP-1 transcription factor complex that binds to AP-1 target sites. NPM1
promoter harbors multiple AP-1 target sites and our data suggest that AP-1 indeed enhances NPM1 gene expression which is relevant in the context of cancer. Further, R175H, a gain-of-function mutant of p53 that has been implicated in the tumorigenesis in several cancers, was also found to have a positive effect on NPM1 expression. The expression of this mutant in cells leads to increase in proliferation, invasion and migration [53] . It is also shown to activate expression of several cell-cycle-related genes such as CCNA2, CCNB2, CDK1 and CDC25C [47, 55] . These genes are targets of transcription factor NF-Y, and R175H has been reported to interact with NF-Y leading to recruitment of R175H to NF-Y target genes with the concomitant transactivation of these genes. Besides NF-Y, R175H also binds to several transcription factors such as Specificity protein 1 (Sp1), nuclear factor kappa B (NF-KB) and vitamin D receptor (VDR) [47] . NPM1 promoter contains binding sites for all the abovementioned transcription factors, and hence, R175H could potentially bind to any one or more of these factors and get recruited onto NPM1 promoter. In Values are mean + SEM from three independent experiments. Statistical significance was calculated using Student's t test. ****P < 0.0001, ns, non-significant.
addition, R175H induces expression of several transcription factors such as MYC proto-oncogene (cmyc), early growth response 1 (EGR1) and nuclear factor kappa B subunit 2 (NF-KB2) [47] ; hence R175H could activate these and induce NPM1 expression. R175H is also known to interact with co-activator CREB-binding protein (CBP)/p300 through its transactivation domain [47, 57] . NPM1 is a reported target of c-myc which gets induced by R175H. Hence there could be multiple possible mechanisms of regulation of NPM1 expression by R175H, and it needs to be confirmed which of these mechanisms or a combination of them is at play. Interestingly, NPM1 has been reported earlier to enhance the stability of R175H and R248W p53 mutants [46] suggesting that there could be a positive feed-back loop connecting these players in promoting tumor progression. Our study suggests the involvement of c-fos as a novel factor regulating NPM1 expression. We also observe an additional synergistic effect of both c-fos and R175H p53 in enhancing NPM1 expression. The overexpression of cfos and mutant p53 along with NPM1 in oral cancer patient tissues suggests the possible existence of this molecular pathway at the physiological level. The reported overexpression of c-fos and mutant p53 in melanoma [58] also supports this view. Although in our studies, another conformational mutant R249S and a DNA contact mutant R273H did not seem to affect NPM1 expression, we cannot rule out the possibility that other p53 mutants that are functionally similar to R175H, might regulate NPM1 expression.
Materials and methods
Cell culture were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA antibiotic. The UM-SCC-1 cells stably harboring the 3xFLAG-R175H p53 in p3xFLAG-CMV10 vector were grown in media containing 0.4 mgÁmL À1 of G418 disulfate salt (Sigma) antibiotic. All the media were supplemented with 10% Fetal Calf Serum (v/v) (Gibco) and 1X antibiotics containing penicillin, streptomycin, and amphotericin (Hi-Media, Mumbai, Maharashtra, India). All cell lines used in this study were tested and found to be mycoplasma negative.
Plasmids
Human genomic DNA was isolated from the blood sample of a healthy individual at Dhanvantari Clinic at JNCASR after obtaining informed consent from the individual, using the Genomic DNA isolation kit (Sigma-Aldrich, St. Louis, MO, USA). The different NPM1 promoter fragments were amplified from this human genomic DNA by PCR using specific primers listed in Table 4 . The fragments were cloned between the Kpn I and Xho I sites of the pGL3 basic vector (Promega, Madison, WI, USA). The c-fos/AP-1-binding sites on the NPM1 Luc 2 (À1059 to +264) plasmid were mutated using the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). The full-length c-fos coding sequence was amplified from HEK293 cDNA using specific primers (Table 4 ) and cloned into the Hind III and Xba I sites of the pFLAG-CMV2 vector (Sigma) resulting in an N-terminal FLAG-tagged cfos construct. The c-fos DNA-binding-deficient mutants were generated by site-directed mutagenesis of FLAG-c-fos plasmid. The c-jun expression plasmid was a kind gift from Dr. Sagar Sengupta (National Institute of Immunology, India). The wild-type p53 (pCMV-wtp53) expression plasmid was a kind gift from Prof. Bert Vogelstein (Johns Hopkins University, Baltimore, MD, USA). The WT p53 coding sequence was amplified by PCR from a pCMVwtp53 template using specific primers (Table 4) and cloned into the Hind III and Bam HI sites of the pFLAG-CMV2 and p3XFLAG-CMV-10 vector (Sigma) resulting into Nterminal FLAG-tagged and 3X-FLAG tagged p53 expression constructs. The gain of function (GOF) p53 mutants R175H, R273H, and R249S expression constructs were generated by site-directed mutagenesis of FLAG-WT p53 using the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene). The 3X-FLAG-R175H construct was generated similarly by site-directed mutagenesis of 3X-FLAG-WT p53 construct. The primer sequences used for various point mutants have been listed in Table 4 . The inducible R175H p53 expression constructs were generated by subcloning the WTp53 and R175Hp53 amplicons into the pEBTetD vector; pEBTetD SLC22A1 vector was a kind gift from Dr. Dirk Gr€ undemann (University of Cologne, Germany). The SLC22A1 insert was released by digestion with Kpn I and Xho I and the R175H p53 insert was cloned into the same site. All constructs were confirmed by insert release and sequencing.
Transient transfection of plasmid DNA in mammalian cells 
Generation of stable cell lines
Stable cell lines were generated in UM-SCC-1 by transfecting them with the 3X-FLAG-R175H construct or the empty vector for a period of 24 h followed by selection with 600 lgÁmL À1 of G418 antibiotic over a period of 7 days. Single cell colonies were selected and characterized for expression of 3X-FLAG-R175H protein. Inducible R175H p53 expressing cell lines were generated by transfecting H1299 cells with pEBTetD-R175H construct for a period of 24 h followed by selection with 1.1 lgÁmL À1 of puromycin over a period of 4 days. Single cell colonies were selected and characterized for doxycycline induced expression of 3X-FLAG-R175H protein. 
Chromatin immunoprecipitation
H1299 cells were maintained in RPMI-1640 supplemented with 10% FBS up to 80% confluency. ChIP experiments were performed as described previously [59] . Briefly, 10-15 million cells seeded in 100 mm dishes were cross-linked using 1% formaldehyde, followed by cell lysis in SDS lysis buffer [1% SDS, 10 mM ethylenediaminetetraacetic acid (EDTA), 50 mM Tris-HCl, pH 8] and subjected to sonication using a Diagenode Bioruptor (Leige, Belgium) to produce DNA fragments of 100-300 bp in length using cold ChIP-dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8, 167 mM NaCl). The lysates were pre-cleared prior to immunoprecipitation with pre-blocked Protein G-Sepharose (Amersham Biosciences, Buckinghamshire, UK) for 1 h. The pull-downs for ChIP assay was performed with anti-FLAG antibody or anti-c-fos antibody and pre-blocked Protein G-Sepharose beads which were incubated overnight. Beads were washed successively with low salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8, and 150 mM NaCl), high salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM TrisHCl, pH 8, and 500 mM NaCl), LiCl buffer (250 mM LiCl, 1% NP40, 1% NaDOC, 1 mM EDTA, and 10 mM Tris-HCl, pH 8), and TE (10 mM Tris-HCl, pH 8, and 1 mM EDTA). Elution buffer (0.2% SDS and 100 mM NaHCO 3 ) was added to the washed beads, and the bead solution was incubated at room temperature (RT) for 30 minutes. The DNA-protein complexes were then reverse cross-linked by adding 200 mM NaCl, 20 lg Proteinase K (Sigma) and incubating at 65°C for 4 h. Subsequently, 20 lg of RNaseA (Sigma) were added and was further incubated for 15 minutes at 37°C. The immunoprecipitated DNA was extracted using phenolchloroform, ethanol precipitated and used for real-time PCR analysis. The region-specific primer sets used for the realtime ChIP-qPCR analysis have been mentioned in Table 4 .
Immunoprecipitation
H1299 cells seeded in 100 mm dishes were co-transfected with FLAG-c-fos and pCMV-R175H p53 constructs for 24 h followed by lysis in FLAG lysis buffer (50 mM TrisHCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 10% glycerol and protease inhibitors). Immunoprecipitation was performed using M2 agarose beads (Sigma) using the manufacturer's protocol. The immunoprecipitated complex was eluted using 3X FLAG-peptide (Sigma) or 1X sample loading buffer followed by heating at 95°C for 10 minutes. The eluted complex was electrophoresed on an SDS/PAGE gel and western blotting was performed with anti-c-fos and anti-p53 antibodies. Immunoprecipitation assays from AU565 cells were performed by lysing 10 million cells in RIPA buffer followed by incubation with 5 lg c-fos antibody or rabbit IgG and 25 lL of Dynabeads Protein G (Invitrogen) overnight. Beads were washed thrice with RIPA buffer and eluted using 1X sample loading buffer. Immunohistochemistry was performed on tumor and adjacent normal tissues as described previously [60] .
Immunohistochemistry and ethics statement
Immunofluorescence
For co-localization studies, H1299 cells were co-transfected with FLAG-R175H and FLAG-c-fos. After 24 h of transfection, cells were washed with 1X PBS and fixed by incubating in 4% paraformaldehyde in 1X PBS for 20 minutes at RT. Fixed cells were washed with wash buffer I (1X PBS) thrice and permeabilized by incubation in permeabilization buffer (1% Triton-X-100 in 1X PBS) for 5 minutes at RT. Cells were subsequently blocked with 5% fetal bovine serum (FBS) in IX PBS for 45 minutes at 37°C, followed by incubation with primary antibodies, anti-p53 and subsequently anti-c-fos for 1 h at RT with intermediate washing with wash buffer II (1% FBS, 0.1% Triton-X-100 in 1X PBS). This was similarly followed by incubation with secondary antibodies anti-rabbit Alexa Fluor 488 and subsequently, anti-mouse Alexa Fluor 633. Immunostained cells were then incubated in 1 lgÁmL À1 of Hoechst 33258 (Sigma) for 5 minutes at RT, washed thrice in 1X PBS and mounted on glass slides using 70% glycerol. For characterization of doxycycline inducible expression of FLAG tagged R175H p53 in H1299 cells, cells were treated with or without doxycycline (Sigma, 1 lgÁmL À1 ) for at least 24 h, followed by immunostaining using primary antibody anti-FLAG and secondary antibody anti-mouse Alexa Fluor 488 as per procedure mentioned above. Imaging was performed in Carl Zeiss LSM 510 Meta Confocal Microscope at the JNCASR Imaging Facility, Bangalore, India.
Statistical analyses
Data are represented as mean and standard error of mean (Mean + SEM). All statistical analyses were performed using GRAPHPAD PRISM 7.0 software (GraphPad Prism Software Inc., San Diego, CA, USA). Comparison between two means were assessed by unpaired two-tailed Student's t test, and that between three or more groups were evaluated using one-way analysis of variance (ANOVA) followed by Tukey's post hoc test. A P-value of <0.05 was considered statistically significant. Figures were generated using ADOBE ILLUSTRATOR software (San Jose, CA, USA).
